TABLE 1 from Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription
收藏数据链接：
官方服务：
资源简介：
Response and pharmacokinetics properties of patients with DH-DLBCL and other patients with MYC+ NHL (n = 15) treated with 30 mg enitociclib i.v. once weekly
15例接受每周1次静脉输注30mg恩替西利（enitociclib）治疗的双打击弥漫大B细胞淋巴瘤（DH-DLBCL）患者及其他MYC阳性非霍奇金淋巴瘤（MYC+ NHL）患者的应答与药代动力学特征
创建时间：
2023-11-09
